IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
IntelGenx Corp. (OTCQB: IGXT; TSX: IGX) has initiated a sale and investment solicitation process (SISP) following a court order under the Companies’ Creditors Arrangement Act (CCAA). The Superior Court of Québec approved the SISP and a purchase agreement with atai Life Sciences AG, establishing a baseline bid for the company's assets. The two-phased SISP process will be monitored by EY, with the first phase bid deadline set for July 15, 2024. Interested parties should contact EY representatives for details. The process aims to attract superior bids and ensure a going-concern solution for IntelGenx.
- Court approval of the SISP process provides a structured path forward.
- The Stalking Horse Bid by atai Life Sciences AG offers a baseline bid, ensuring the company's assets have a minimum value.
- EY's involvement as the monitor adds credibility and structure to the process.
- The SISP process aims to attract superior bids, potentially increasing the final sale value.
- The need for a CCAA proceeding indicates financial distress and potential insolvency.
- Initiation of a sale process may create uncertainty among investors and stakeholders.
- The company’s dependence on attracting superior bids introduces risk if no better offers are made.
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”).
On May 27, 2024, the Court granted an order (the “SISP Order”) which i) approved a sale and investment solicitation process to be conducted in respect of the business and/or assets of the Company (the “SISP”), and ii) approved the agreement of purchase and sale between IntelGenx, as vendor, and atai Life Sciences AG, as purchaser, solely for the purpose of constituting the “stalking horse” bid under the SISP (the “Stalking Horse Bid”). The Stalking Horse Bid establishes a baseline price and deal structure for the solicitation of superior bids from qualified interested parties and provides certainty that a going-concern solution for the business of IntelGenx has already been identified.
Ernst & Young Orenda Corporate Finance Inc. and its affiliate, Ernst & Young Corporate Finance (Canada) Inc. shall be assisting the Company and the Monitor in connection with the SISP process.
The SISP is a two-phased process with the Phase 1 bid deadline set for July 15, 2024. Parties interested in the opportunity should contact the Monitor via one of the persons listed below to get further details.
| Jatinder Wadhwa(1) Senior Vice President +1 416 943 3078 jatinder.wadhwa@ca.ey.com | Mansa Singh Senior Associate +1 416 932 4902 mansa.singh@ca.ey.com | Jessica Jingwei Analyst +1 416 932 4424 jessica.jingwei@ca.ey.com |
| Martin Rosenthal Senior Vice President +1 514 879 6549 martin.rosenthal@parthenon.ey.com | Martin Carrière Senior Vice President +1 514 879 3254 martin.carriere@parthenon.ey.com | Alexandre Ferland Director +1 514 943 0929 alexandre.ferland@parthenon.ey.com |
Copies of the SISP Order and the SISP procedures may be obtained from the website of the Monitor at www.ey.com/ca/intelgenx.
(1) Any inquiries by U.S. persons should be directed to Ernst & Young Corporate Finance (Canada) Inc. through Jatinder Wadhwa.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm® and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit https://www.intelgenx.com/ and connect with us on X and LinkedIn.
FAQ
What is IntelGenx's SISP?
What is the significance of the Stalking Horse Bid in IntelGenx's SISP?
When is the Phase 1 bid deadline for IntelGenx's SISP?
Who is monitoring IntelGenx's SISP process?
What does the court order under the CCAA mean for IntelGenx?
